BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26597578)

  • 1. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
    Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
    Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice.
    Khan F; Gurung S; Gunassekaran GR; Vadevoo SMP; Chi L; Permpoon U; Haque ME; Lee YK; Lee SW; Kim S; Lee B
    Theranostics; 2021; 11(3):1326-1344. PubMed ID: 33391537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
    Chen ZH; Yu YP; Tao J; Liu S; Tseng G; Nalesnik M; Hamilton R; Bhargava R; Nelson JB; Pennathur A; Monga SP; Luketich JD; Michalopoulos GK; Luo JH
    Gastroenterology; 2017 Oct; 153(4):1120-1132.e15. PubMed ID: 28245430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
    Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
    Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
    Wu W; Bi C; Credille KM; Manro JR; Peek VL; Donoho GP; Yan L; Wijsman JA; Yan SB; Walgren RA
    Clin Cancer Res; 2013 Oct; 19(20):5699-710. PubMed ID: 23989980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.
    Tremmel M; Matzke A; Albrecht I; Laib AM; Olaku V; Ballmer-Hofer K; Christofori G; Héroult M; Augustin HG; Ponta H; Orian-Rousseau V
    Blood; 2009 Dec; 114(25):5236-44. PubMed ID: 19773544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.
    Li L; Hao X; Qin J; Tang W; He F; Smith A; Zhang M; Simeone DM; Qiao XT; Chen ZN; Lawrence TS; Xu L
    Gastroenterology; 2014 Apr; 146(4):1108-18. PubMed ID: 24397969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
    Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
    Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
    Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
    Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
    Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.
    Yan HH; Jung KH; Son MK; Fang Z; Kim SJ; Ryu YL; Kim J; Kim MH; Hong SS
    Oncotarget; 2014 Oct; 5(19):9150-68. PubMed ID: 25193856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
    Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
    J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer.
    Takiguchi S; Inoue K; Matsusue K; Furukawa M; Teramoto N; Iguchi H
    Int J Oncol; 2017 Jul; 51(1):184-192. PubMed ID: 28498406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
    Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
    Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.